Zoledronic Acid CAS 118072-93-8 Ubunyulu ≥99.7% API Factory High Quality
Ukubonelela ngoBusulungekileyo obuPhezulu kunye noMgangatho oZinzileyo
Igama leKhemikhali: I-Zoledronic Acid
CAS: 118072-93-8
I-Farnesyl Diphosphate enamandla (FPP) i-Synthase Inhibitor
Umgangatho ophezulu we-API, iMveliso yoRhwebo
| Igama leMchiza | I-Zoledronic Acid |
| Izithethantonye | ZOL 446, ZA, Zoledronate, CGP-4244, GP42446A, Zometa, Zomera;[1-Hydroxy-2-(1H-imidazol-1-yl)-ethylidene]bisphosphonic acid |
| Inombolo yeCAS | 118072-93-8 |
| Inombolo yeCAT | RF-API90 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | I-C5H10N2O7P2 |
| Ubunzima beMolekyuli | 272.09 |
| Indawo yokunyibilika | 193.0 ~ 204.0℃ |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Mhlophe ukuya kuMhlophe oMhlophe wePowder |
| Ukuchongwa | I-IR Spectrum yesampuli ihambelana naleyo yomgangatho wereferensi |
| pH | 2.0~4.0 |
| Ukunyibilika | Inyibilika kancinane kwi-0.1N yeSodium Hydroxide Solution, iNyibilika kancinane emanzini kunye ne-0.1N Hydrochloric Acid, ayiNyibiliki kwi-Ethanol |
| Izinto ezinxulumeneyo | |
| Nakuphi na Ukungacoceki komntu | ≤0.10% |
| Ukungcola ngokupheleleyo | ≤0.30% |
| Ilahleko ekomisweni | 5.0%~7.0% |
| I-Chloride | ≤0.02% |
| Phosphite | ≤0.50% |
| Iphosphate | ≤0.50% |
| Iintsimbi ezinzima | ≤10ppm |
| Ubunyulu | ≥99.7% |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | API, FPP Synthase Inhibitor, Hypercalcemia of Malignancy (HCM) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Zoledronic Acid (i-CAS 118072-93-8) i-bisphophonate enamandla farnesyl diphosphate (FPP) synthase inhibitor (IC50 = 20 nM).Inqanda i-osteoclast-mediated bone resorption.Kwakhona inqanda ukubonakaliswa kweRas kunye nokukhula kwethumba, kwaye ibangela i-apoptosis kwiiseli zomhlaza wepancreatic.Iguqula inguqu ye-epithelial-mesenchymal kwaye inqanda ukuhlaziywa kweseli yomhlaza webele ngokungasebenzi kwe-NF-kB.I-asidi ye-Zoledronic yamkelwa yi-US FDA kwi-2001 yonyango lwe-hypercalcemia ye-malignancy, i-complication ye-metabolic enokubeka ubomi esichengeni.I-Hypercalcemia ye-malignancy ingenzeka ukuya kuthi ga kwi-50% yezigulana ezifunyaniswe zinomhlaza webele ophezulu, i-myeloma eninzi, kunye nomhlaza wemiphunga weseli ongemncinci.Le meko ivela xa i-chemical moieties eveliswa yi-tumor ibangela ukugqithiswa kwe-osteoclasts.Xa kukho ukwanda kwamathambo, kukho ukukhutshwa okuhambelanayo kwe-calcium kwi-plasma.Xa i-serum concentrations ye-calcium iphakamisa ngokukhawuleza, izintso azikwazi ukuphatha ukugqithiswa, kwaye iziphumo ze-hypercalcemia.I-Zoledronic acid iyancipha ngokufanelekileyo i-plasma calcium concentrations ngokuvinjelwa kwe-bone resorption (ukuthintela umsebenzi we-osteoclastic kunye nokungeniswa kwe-osteoclast apoptosis).Ukongeza i-zoledronic acid ivunyiwe yi-US FDA yonyango lwe-myeloma emininzi kunye ne-bone metastases ehambelana nomhlaza oqinileyo osekelwe kwithumba (umzekelo, ukuguqa kunye nemiphunga).
